SynthesisClinical endocrinology2022
Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis.
Synthesis in Clinical endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Role of the calcium stimulation test in diagnosing medullary thyroid cancer: is it adequate to achieve a diagnosis in both sexes? An individual patient data meta-analysis.European thyroid journal · 2025Pooled it
- Pooled it
- Prevalence and significance of indeterminate calcitonin values in patients with thyroid nodules: A systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2023Pooled it
- Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis.Clinical endocrinology · 2022Pooled it
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
- Using Elastographic Stiffness to Improve Risk Stratification in Medullary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Analysis of FNAC indication in thyroid nodules assessed as low risk according to various TIRADSs.European thyroid journal · 2025Article
- Clinical management of indeterminate thyroid nodules needs to be revisited. New evidence for a personalized approach to the problem.Journal of endocrinological investigation · 2025Observational
- Review
- Meaning of ACR-TIRADS recommendation in favor of follow-up rather than FNAC in thyroid nodules.Updates in surgery · 2024Article
- Risk of TIRADS-based inappropriate FNAC in autonomous thyroid nodules is clinically negligible.European thyroid journal · 2024Article
- Prediction of classical versus non classical papillary thyroid carcinoma subtypes from cytology of nodules classified according to TIRADS.Endocrine · 2024Article
- Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities.Reviews in endocrine & metabolic disorders · 2024Review
- Thyroid ultrasound and its ancillary techniques.Reviews in endocrine & metabolic disorders · 2024Review
- Article
- Comparative Analysis of AI-SONICTM Thyroid System and Six Thyroid Risk Stratification Guidelines in Papillary Thyroid Cancer: A Retrospective Cohort Study.Therapeutics and clinical risk management · 2024Article
- Appropriate and mindful measurement of serum calcitonin in patients with thyroid nodules. A white paper.Endocrine · 2024Article
- Evaluation of the Performance of ACR TI-RADS Also Considering Those Nodules with No Indication of FNAC: A Single-Center Experience.Journal of clinical medicine · 2023Article
- Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUltrasound (US) is the pivotal procedure during the diagnostic work-up of thyroid nodule and several US-based risk stratification systems (RSSs) have been recently developed. Since the performance of RSSs in detecting medullary thyroid carcinoma (MTC) has been rarely investigated, the present systematic review aimed to achieve high evidence about (1) how MTC is classified according to RSSs; (2) if RSSs correctly classify MTC at high risk/suspicion, and (3) if MTC is classified as suspicious at US when RSSs are not used.
designThe review was performed according to MOOSE. The online search was performed by specific algorithm on January 2022. A random-effects model was used for statistical analysis.
resultsTwenty-five papers were initially included and their risk of bias was generally low. According to ATA system, 65% of MTCs was assessed at high suspicion and 25% at intermediate suspicion. Considering all RSSs, a 54.8% of MTCs was put in a high-risk/suspicion category. Pooling data from studies without data of RSS the prevalence of ultrasonographically suspicious MTCs was 60%.
conclusionsAs conclusion, MTC presentation according to RSSs is partially known and it is classified in a high-risk/suspicion category of RSSs in just over a half of cases. This advises for further studies, ideally supported by international societies, to better define the US presentation of MTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.